# US 2026/0028335 A1 · Novel isothiazol-3-yl and isoxazol-3-yl sulfonamide compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028335 A1
- Document ID: US20260028335A1
- Status: Published application
- Kind: A1
- Application number: 18/993,989
- Filed: 2023-07-18
- Published: 2026-01-29
- Earliest claimed: 2022-07-20
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Guido GALLEY; Luca Claudio GOBBI; Wolfgang GUBA; Dmitry MAZUNIN; Emmanuel PINARD; Antonio RICCI
- Web page: https://patentgrep.com/patent/US20260028335A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, X and Y are as described herein, composition including the compounds and methods of using the compounds.

## Claims

### Claim 1

Compounds of formula I
wherein,
R1 is alkyl, alkoxy, cyano, cyanoalkyl, cyclopropyl, or halo;
R2 is H, alkyl, alkoxy, cyano, cyclopropyl or halo;
R3 is halo, alkyl, or haloalkyl;
X is —O— or —S—;
Y is CH or N;
and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R1 is alkyl, alkoxy, cyanoalkyl or cyclopropyl.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein R2 is H, alkyl, alkoxy, cyano, cyclopropyl or halo.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein R2 is alkoxy or halo.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein R3 is halo or alkyl.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein R3 is halo.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein X is —S—.

### Claim 8 (depends on 1)

A compound according to claim 1 wherein
R1 is alkyl, alkoxy, cyanoalkyl, or cyclopropyl;
R2 is H, alkyl, alkoxy, cyano, cyclopropyl or halo;
R3 is halo;
X is —O— or —S—;
Y is CH or N;
and pharmaceutically acceptable salts thereof.

### Claim 9 (depends on 1)

A compound according to claim 1 wherein
R1 is alkyl, alkoxy, cyanoalkyl, or cyclopropyl;
R2 is alkoxy or halo;
R3 is halo;
X is —S—;
Y is CH or N;
and pharmaceutically acceptable salts thereof.

### Claim 10 (depends on 1)

A compound according to claim 1, selected from
6-chloro-N-(4-chloro-5-propyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-chloro-5-cyclopropyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-chloro-5-cyclopropyl-isothiazol-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide;
6-bromo-N-(4-chloro-5-cyclopropyl-isothiazol-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide;
6-chloro-N-(4-chloro-5-methyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4,5-dimethylisothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(5-ethyl-4-methyl-isoxazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-chloro-5-ethyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-ethyl-5-methyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-chloro-5-methoxy-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-chloro-5-ethoxy-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-[4-chloro-5-(2-cyanoethyl)isothiazol-3-yl]-1H-indole-3-sulfonamide;
6-chloro-N-(5-methylisothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-cyclopropyl-5-methyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-cyano-5-methyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-methoxy-5-methyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-methoxy-5-propyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-methyl-5-propyl-isoxazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4,5-dimethylisoxazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-chloro-5-methyl-isoxazol-3-yl)-1H-indole-3-sulfonamide;
N-(4-bromo-5-methyl-isoxazol-3-yl)-6-chloro-1H-indole-3-sulfonamide;
and pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 1)

A compound according to claim 1, selected from
6-chloro-N-(4-chloro-5-propyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-chloro-5-cyclopropyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-bromo-N-(4-chloro-5-cyclopropyl-isothiazol-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide;
6-chloro-N-(4-chloro-5-methyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-chloro-5-ethyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-(4-chloro-5-ethoxy-isothiazol-3-yl)-1H-indole-3-sulfonamide;
6-chloro-N-[4-chloro-5-(2-cyanoethyl)isothiazol-3-yl]-1H-indole-3-sulfonamide;
6-chloro-N-(4-methoxy-5-propyl-isothiazol-3-yl)-1H-indole-3-sulfonamide;
and pharmaceutically acceptable salts thereof.

### Claim 12 (depends on 1)

A process to prepare a compound according to claim 1 comprising the reacting a compound of formula III with a compound of formula II in the presence of a base selected from N-ethyldiisopropylamine or pyridine with or without the addition of the catalyst 4-dimethylaminopyridine, or in the presence of an inorganic base like potassium phosphate, to provide a compound of formula I,
wherein R1, R2, R3, X and Y are as described above.

### Claim at position 13

13-14. (canceled)

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a therapeutically inert carrier.

### Claim at position 15

16-20. (canceled)

### Claim 21 (depends on 1)

A method for the treatment or prophylaxis of conditions resulting from direct damage to myelin sheaths (including but not limited central pontine and extra-pontine myelinolysis, carbon monoxide poisoning, nutritional deficiency, and virus-induced demyelination), demyelinating disorders (including but not limited to multiple sclerosis, acute and multiphasic disseminated encephalomyelitis, neuromyelitis optica spectrum disorders, and leukodystrophies), CNS disorders associated with myelin loss (including but not limited to Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, and Ischemia due to stroke), and inflammation in the CNS for instance following encephalitis, primary angiitis, meningitis and obesity, which method comprises administering an effective amount of a compound of claim 1 to a patient in need thereof.

### Claim 22 (depends on 1)

A method for the treatment or prophylaxis of multiple sclerosis, which method comprises administering an effective amount of a compound of claim 1 to a patient in need thereof.

### Claim at position 18

23-24. (canceled)
